Stillen’s sales in December top 6.8 billion won

Dong-A Pharma’s Stillen, Korea’s homegrown anti-ulcerant medicine, recorded 6.8 billion won in sales last December, a 31 percent jump from 2007, leading the domestic market, according to Ubist.

The market’s second player, Jeil Pharm, saw a 77.4 percent increase in last year’s December sales (3.0 billion won), followed by Daewoong Pharm with 2.6 billion won and Pacific Pharm with 2.3 billion ...